Royalty Pharma plc (RPRX)
Upgrades & Downgrades
Latest RPRX news
Royalty Pharma: The Time Has Come
27 September 2023
Royalty Pharma offers a unique exposure in the pharmaceutical sector thanks to a diversified portfolio and lower operational risk vs. competitors. The Vertex franchise is a significant contributor to ...
Royalty Pharma: We Continue To Like The Strategy And Sell-Off Is Overdone
5 September 2023
Q2 2023 earnings showcasted robust performance and raised forecast for 2023 non-GAAP adjusted cash receipts. Royalty Pharma enters strategic partnership with Ferring Pharmaceuticals, investing $300 mi...
Royalty Pharma to Present at Upcoming Investor Conferences
5 September 2023
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:
Andreas Halvorsen's Firm Ups Inhibrx Stake
1 September 2023
Viking Global Investors, the investment firm founded by Andreas Halvorsen (Trades, Portfolio) in 1999, disclosed earlier this week it boosted its stake in Inhibrx Inc. ( INBX , Financial) by 7.71% fol...
Royalty Pharma (RPRX) Surpasses Q2 Earnings and Revenue Estimates
8 August 2023
Royalty Pharma (RPRX) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.79 per share a year ago.
Why Royalty Pharma (RPRX) Might Surprise This Earnings Season
7 August 2023
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2 Dividend Stocks Wall Street Thinks Can Rise by 50%
26 July 2023
Royalty Pharma and JD.com both provide investors with above-average dividend yields. Royalty Pharma's business model relies on royalty payments, making it suitable for income investors.
Royalty Pharma: Not Quite In The 'Buy Zone' Yet
19 July 2023
Shares of biopharmaceutical royalty concern Royalty Pharma plc have fallen 45% from their all-time high as inflation and a potential revenue decline from its number one asset weigh. Vertex Pharmaceuti...
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
18 July 2023
NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023 before the U.S. f...